Table of Contents
The human body’s immune response involves a complex network of chemical mediators that help defend against infections and injuries. Among these mediators, leukotrienes play a significant role in promoting inflammation and bronchoconstriction, especially in respiratory conditions such as asthma.
What Are Leukotrienes?
Leukotrienes are lipid compounds derived from arachidonic acid through the action of the enzyme 5-lipoxygenase. They are part of the eicosanoid family, which includes prostaglandins and thromboxanes. Leukotrienes are produced mainly by white blood cells, including mast cells, eosinophils, and macrophages.
The Role of Leukotrienes in Inflammation
Leukotrienes contribute to inflammation by increasing vascular permeability, attracting immune cells to the site of injury or infection, and promoting the release of other inflammatory mediators. They are potent chemotactic agents that help coordinate the immune response.
Mechanisms of Inflammatory Action
- Vasodilation: Leukotrienes cause dilation of blood vessels, leading to redness and swelling.
- Vascular permeability: They increase the leakiness of blood vessels, allowing immune cells and proteins to reach affected tissues.
- Cell recruitment: Leukotrienes attract eosinophils and other immune cells to sites of inflammation.
Leukotrienes and Bronchoconstriction
In the respiratory system, leukotrienes have a profound effect on airway smooth muscle, leading to bronchoconstriction. This narrowing of the airways is a hallmark of asthma and other allergic airway diseases.
Mechanisms of Bronchoconstriction
- Smooth muscle contraction: Leukotrienes bind to specific receptors on airway smooth muscle cells, causing them to contract.
- Mucus production: They stimulate mucus-secreting glands, increasing mucus in the airways and further obstructing airflow.
- Inflammatory cell activation: Leukotrienes activate eosinophils and other immune cells, which release additional inflammatory mediators.
Clinical Significance
Understanding the role of leukotrienes has led to targeted therapies for asthma and allergic rhinitis. Leukotriene receptor antagonists, such as montelukast and zafirlukast, block the action of leukotrienes, reducing inflammation and bronchoconstriction.
Conclusion
Leukotrienes are critical mediators in the inflammatory response and airway constriction. Their modulation offers valuable therapeutic options for managing respiratory diseases characterized by inflammation and bronchospasm.